{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:17:53Z","timestamp":1783570673369,"version":"3.55.0"},"reference-count":57,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Classical Hodgkin lymphoma (cHL) remains one of the most curable hematologic malignancies, with long-term survival exceeding 80\u201390% in most contemporary series. However, a subset of patients experience primary refractory disease, relapse, treatment-related toxicity, or late complications associated with conventional chemotherapy and radiotherapy. Over the last decade, major advances in frontline treatment have transformed the therapeutic landscape of cHL through the incorporation of targeted therapy and immune checkpoint inhibition into first-line regimens. Brentuximab vedotin (BV), an anti-CD30 antibody\u2013drug conjugate, and programmed death-1 (PD-1) inhibitors such as nivolumab and pembrolizumab have significantly improved outcomes in advanced-stage disease and are increasingly being explored in limited-stage settings. The ECHELON-1 trial established BV-AVD as superior to ABVD in advanced-stage disease with improved progression-free survival and overall survival, while the SWOG S1826 study demonstrated superior progression-free survival and reduced toxicity with nivolumab-AVD compared with BV-AVD. Based on the SWOG S1826 data, nivolumab-AVD is emerging as the preferred frontline standard for most fit patients with advanced-stage cHL, though this remains an area of evolving practice. PET-adapted strategies remain a critical backbone of treatment optimization even in the era of novel agents, enabling individualized de-escalation or escalation based on early metabolic response. These advances have shifted frontline treatment paradigms toward chemotherapy de-escalation, PET-adapted strategies, and immune-based treatment approaches. In parallel, the role of radiotherapy continues to evolve with efforts aimed at minimizing long-term toxicity without compromising cure rates, particularly in PET-negative patients with limited-stage disease. This review summarizes the biological rationale, pivotal clinical trials, evolving treatment strategies, current guideline recommendations, and future directions in first-line treatment of cHL, with emphasis on evidence-based incorporation of novel agents and practical implications for modern clinical practice.<\/jats:p>","DOI":"10.3390\/jcm15135075","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:55:11Z","timestamp":1782780911000},"page":"5075","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances in First-Line Treatment of Classical Hodgkin Lymphoma in the Era of Novel Agents"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-3817","authenticated-orcid":false,"given":"Ahmed Salleh","family":"Barefah","sequence":"first","affiliation":[{"name":"Hematology Department, Faculty of Medicine, King Abdulaziz University Hospital, King Abdulaziz University, Jeddah 21589, Saudi Arabia"},{"name":"Hematology Research Unit, King Fahad Medical Research Center, King Abdulaziz University, Jeddah 21859, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/PPO.0b013e31819e30d7","article-title":"Late complications of Hodgkin lymphoma treatment","volume":"15","author":"Ng","year":"2009","journal-title":"Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/ajh.27470","article-title":"Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management","volume":"99","author":"Ansell","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_3","first-page":"116","article-title":"Hodgkin lymphoma: A review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1200\/JCO.2008.19.8820","article-title":"Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin\u2019s lymphoma: 10 years of follow-up of the GHSG HD9 study","volume":"27","author":"Engert","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","first-page":"3896","article-title":"Brentuximab vedotin in relapsed CD30-positive lymphomas","volume":"28","author":"Younes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab plus AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Miljak, A., Pavlovi\u0107, A., Benzon, B., \u010cutura, L.V., Galu\u0161i\u0107, D., Vuj\u010di\u0107, M., Blaslov, V., and Durdov, M.G. (2025). High PD-L1 Expression in HRS Cells and Macrophages in Tumor Immune Microenvironment Is Associated with Adverse Outcome and EBV Positivity in Classical Hodgkin Lymphoma. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26125592"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM199211193272102","article-title":"Chemotherapy of advanced Hodgkin\u2019s disease with MOPP, ABVD, or MOPP alternating with ABVD","volume":"327","author":"Canellos","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1200\/JCO.2005.02.7243","article-title":"Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin\u2019s lymphoma","volume":"23","author":"Martin","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa022473","article-title":"Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin\u2019s disease","volume":"348","author":"Diehl","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.annonc.2025.07.014","article-title":"Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Eyre","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_17","unstructured":"National Comprehensive Cancer Network (2025). NCCN Clinical Practice Guidelines in Oncology: Hodgkin Lymphoma, NCCN. Version 1.2026."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0140-6736(24)01315-1","article-title":"Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): A randomised, multicentre, parallel, open-label, phase 3 trial","volume":"404","author":"Borchmann","year":"2024","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1200\/JCO.2007.11.6525","article-title":"Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin\u2019s lymphoma","volume":"25","author":"Gallamini","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Tutino, F., Giovannini, E., Chiola, S., Giovacchini, G., and Ciarmiello, A. (2023). Assessment of response to immunotherapy in patients with Hodgkin lymphoma: Towards quantifying changes in tumor burden using FDG-PET\/CT. J. Clin. Med., 12.","DOI":"10.3390\/jcm12103498"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1053\/j.semnuclmed.2022.10.006","article-title":"PET\/CT in Hodgkin lymphoma: An update","volume":"53","author":"Mottaghy","year":"2023","journal-title":"Semin. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood-2025-351","article-title":"Circulating tumor DNA analyses of molecular tumor burden are superior to PET-assessed responses in patients with advanced-stage classical Hodgkin lymphoma treated on SWOG S1826","volume":"146","author":"Paczkowska","year":"2025","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood.2024027355","article-title":"A comprehensive genetic study of classic Hodgkin lymphoma using circulating tumor DNA","volume":"146","author":"Pirosa","year":"2025","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cpet.2021.09.006","article-title":"Artificial Intelligence in Lymphoma PET Imaging:: A Scoping Review (Current Trends and Future Directions)","volume":"17","author":"Hasani","year":"2022","journal-title":"PET Clin."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1182\/blood.2020007400","article-title":"Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma","volume":"137","author":"Allen","year":"2021","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.2024024681","article-title":"Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma","volume":"145","author":"Lee","year":"2025","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2025030190","article-title":"Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma","volume":"147","author":"Abramson","year":"2026","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.21.01281","article-title":"Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable Hodgkin lymphoma: Final analysis of the randomized phase II BREACH study","volume":"41","author":"Fornecker","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classical Hodgkin lymphoma: The randomized phase II NIVAHL trial","volume":"6","author":"Brockelmann","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","article-title":"Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older","volume":"126","author":"Holkova","year":"2015","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/blood-2017-06-787200","article-title":"Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged 60 years and older with HL","volume":"130","author":"Friedberg","year":"2017","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter phase II study of sequential brentuximab vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO-25-00204","article-title":"Nivolumab-AVD versus brentuximab vedotin-AVD in older patients with advanced-stage classic Hodgkin lymphoma enrolled on S1826","volume":"43","author":"Rutherford","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2025006","DOI":"10.1007\/s44313-025-00084-4","article-title":"Treatment of older patients with Hodgkin lymphoma","volume":"60","author":"Park","year":"2025","journal-title":"Blood Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Lazarovici, J., Amorim, S., Bouabdallah, K., Fournier, M., Guidez, S., Molina, L., Morschhauser, F., Delapierre, B., Gastinne, T., and Laribi, K. (2026). Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: The NIVINIHO phase II LYSA study. Haematologica, early view.","DOI":"10.3324\/haematol.2025.300166"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1532-5415.1995.tb06377.x","article-title":"Validation of the Cumulative Illness Rating Scale in a geriatric residential population","volume":"43","author":"Parmelee","year":"1995","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1200\/JCO.2015.65.8864","article-title":"No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy","volume":"34","author":"Demeestere","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2015.62.4445","article-title":"Hematologic malignancies in pregnancy: Management guidelines from an international consensus meeting","volume":"34","author":"Lishner","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2011.41.4193","article-title":"HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with ABVD in the highly active antiretroviral therapy era","volume":"30","author":"Montoto","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2015-05-615872","article-title":"How I treat posttransplant lymphoproliferative disorders","volume":"126","author":"Dierickx","year":"2015","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100403","DOI":"10.1016\/j.esmoop.2022.100403","article-title":"Managing hematological cancer patients during the COVID-19 pandemic: An ESMO-EHA Interdisciplinary Expert Consensus","volume":"7","author":"Buske","year":"2022","journal-title":"ESMO Open"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin lymphoma (RAPID)","volume":"372","author":"Radford","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1182\/blood-2025-2738","article-title":"The influence of age on patient-reported outcomes (PROs) endpoints on the S1826 cross-network Phase III trial of advanced-stage, classic Hodgkin lymphoma (cHL)","volume":"146","author":"Davison","year":"2025","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Cashen, A.F. (2024). The evolving role of checkpoint inhibitors in the treatment of Hodgkin lymphoma. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1392653"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"e70126","DOI":"10.1002\/hem3.70126","article-title":"Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high-risk relapsed\/refractory Hodgkin lymphoma","volume":"9","author":"Mei","year":"2025","journal-title":"HemaSphere"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1182\/blood-2010-09-288373","article-title":"How I treat relapsed and refractory Hodgkin lymphoma","volume":"117","author":"Kuruvilla","year":"2011","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin lymphoma at risk of relapse or progression (AETHERA)","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","article-title":"Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study \u2013 a prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/Trasplante de M\u00e9dula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: A prospective study","volume":"106","author":"Camus","year":"2021","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1080\/10428194.2022.2095623","article-title":"AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: Final results of an open-label, randomized, multicenter phase II trial","volume":"63","author":"Sasse","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41591-025-03640-8","article-title":"Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: A phase\u20091 trial","volume":"31","author":"Nieto","year":"2025","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"12728","DOI":"10.1182\/blood-2022-157131","article-title":"Phase 1b\/2 study of autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (ACTION)","volume":"140","author":"Mei","year":"2022","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5075\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:12:14Z","timestamp":1783570334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/13\/5075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,29]]},"references-count":57,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["jcm15135075"],"URL":"https:\/\/doi.org\/10.3390\/jcm15135075","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,29]]}}}